Intra-Cellular Therapies (NASDAQ:ITCI) Rating Reiterated by UBS Group

Intra-Cellular Therapies (NASDAQ:ITCI)‘s stock had its “neutral” rating reiterated by stock analysts at UBS Group in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $83.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $85.00. UBS Group’s target price would indicate a potential upside of 16.75% from the stock’s current price.

A number of other analysts have also commented on ITCI. Cantor Fitzgerald restated an “overweight” rating and issued a $120.00 price target on shares of Intra-Cellular Therapies in a report on Friday, June 14th. Mizuho boosted their price target on Intra-Cellular Therapies from $96.00 to $100.00 and gave the company a “buy” rating in a report on Friday, June 21st. The Goldman Sachs Group boosted their price target on Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a “neutral” rating in a report on Wednesday, April 17th. Robert W. Baird boosted their price target on Intra-Cellular Therapies from $83.00 to $103.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $103.00 price target on shares of Intra-Cellular Therapies in a report on Tuesday. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $94.33.

Intra-Cellular Therapies Trading Down 1.8 %

NASDAQ:ITCI opened at $71.09 on Tuesday. Intra-Cellular Therapies has a 1 year low of $45.50 and a 1 year high of $84.89. The stock has a market cap of $7.50 billion, a price-to-earnings ratio of -61.28 and a beta of 0.97. The stock has a 50-day moving average price of $69.49 and a two-hundred day moving average price of $68.95.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. Intra-Cellular Therapies had a negative return on equity of 18.49% and a negative net margin of 21.57%. The firm had revenue of $144.90 million during the quarter, compared to analysts’ expectations of $141.41 million. During the same period in the previous year, the firm earned ($0.46) earnings per share. The company’s revenue was up 52.0% on a year-over-year basis. Sell-side analysts forecast that Intra-Cellular Therapies will post -0.51 earnings per share for the current year.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, Director Nostrand Robert L. Van sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $75.91, for a total transaction of $1,518,200.00. Following the transaction, the director now owns 9,690 shares of the company’s stock, valued at $735,567.90. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, Director Rory B. Riggs sold 4,462 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $75.57, for a total value of $337,193.34. Following the transaction, the director now owns 116,600 shares of the company’s stock, valued at $8,811,462. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Nostrand Robert L. Van sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $75.91, for a total value of $1,518,200.00. Following the completion of the transaction, the director now directly owns 9,690 shares in the company, valued at approximately $735,567.90. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.

Hedge Funds Weigh In On Intra-Cellular Therapies

Institutional investors and hedge funds have recently made changes to their positions in the company. Kapitalo Investimentos Ltda acquired a new position in shares of Intra-Cellular Therapies in the fourth quarter valued at approximately $26,000. Headlands Technologies LLC acquired a new stake in Intra-Cellular Therapies during the first quarter worth approximately $32,000. Signaturefd LLC grew its position in Intra-Cellular Therapies by 85.7% during the fourth quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 239 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in Intra-Cellular Therapies during the third quarter worth approximately $45,000. Finally, Fidelis Capital Partners LLC acquired a new stake in Intra-Cellular Therapies during the first quarter worth approximately $53,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.